35% slowing on iADRS in low/medium tau population; 2nd FDA-approved disease-modifier (Kisunla, July 2024).
Details
- nct_id
- NCT04437511
- phase
- phase_3
- status
- completed
- domain
- alzheimers
- indication
- Early Symptomatic Alzheimer's Disease
- intervention
- Donanemab (anti-N3pG amyloid)
- sponsor
- Eli Lilly
- n_enrolled
- 1736
- primary_endpoint
- Integrated AD Rating Scale (iADRS) at 76 weeks
Raw fields (1)
- metadata
{}